Search

Your search keyword '"Suttorp, Norbert"' showing total 1,266 results

Search Constraints

Start Over You searched for: Author "Suttorp, Norbert" Remove constraint Author: "Suttorp, Norbert"
1,266 results on '"Suttorp, Norbert"'

Search Results

1. Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in COVID-19

3. Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP)

6. Genetic Regulation of Cytokine Response in Patients with Acute Community-acquired Pneumonia

7. The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation

8. ADAM8 signaling drives neutrophil migration and ARDS severity

9. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01

10. Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study

11. Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies

12. Functional limitations 12 months after SARS-CoV-2 infection correlate with initial disease severity: An observational study of cardiopulmonary exercise capacity testing in COVID-19 convalescents

13. Highly multiplexed immune repertoire sequencing links multiple lymphocyte classes with severity of response to COVID-19

14. Transcriptomic comparison of primary human lung cells with lung tissue samples and the human A549 lung cell line highlights cell type specific responses during infections with influenza A virus

15. Human alveolar progenitors generate dual lineage bronchioalveolar organoids

17. Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months

18. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

19. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01

21. A time-resolved proteomic and prognostic map of COVID-19

22. Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany

23. Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February-March 2021

24. Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19

25. CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity

26. Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections

27. Evaluation of PEEP and prone positioning in early COVID-19 ARDS

28. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis

31. Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19

32. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

33. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis

34. Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19)

36. Preclinical analyses reveal spleen tyrosine kinase as regulator of pulmonary vasoconstriction

39. Inflammasomes in Pneumococcal Infection: Innate Immune Sensing and Bacterial Evasion Strategies

42. Hepatobiliary long-term consequences of COVID-19: dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients.

43. Neutralizing Complement C5a Protects Mice with Pneumococcal Pulmonary Sepsis

45. Antibiotic treatment-induced secondary IgA deficiency enhances susceptibility to Pseudomonas aeruginosa pneumonia

46. Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses

47. Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients

48. Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial

49. A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection

Catalog

Books, media, physical & digital resources